Pharmacoeconomic review report: Empagliflozin and Metformin fixed-dose combination (Synjardy)

Empagliflozin (EMPA)/metformin (MET) fixed-dose combination (FDC) tablet (Synjardy) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone, MET and a sulfonylurea (SU), MET and pioglitazo...

Full description

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health September 2017, 2017
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Empagliflozin (EMPA)/metformin (MET) fixed-dose combination (FDC) tablet (Synjardy) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone, MET and a sulfonylurea (SU), MET and pioglitazone (PIO), or MET and insulin; or when EMPA and MET are already being co-administered as separate tablets with or without an SU, PIO, or insulin. The manufacturer is seeking reimbursement for adult patients with T2DM who are already stabilized on therapy with MET and EMPA, to replace the individual components
Physical Description:1 PDF file (16 pages)